

MOTAZOL- gentamicin sulfate, mometasone furoate monohydrate, and clotrimazole suspension
MWI

VET one®

MotaZol™

(GENTAMICIN SULFATE, MOMETASONE FUROATE MONOHYDRATE, AND CLOTRIMAZOLE, OTIC SUSPENSION)

VETERINARY

For Otic Use in Dogs Only

CAUTION Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Keep this and all drugs out of the reach of children.

DESCRIPTION Each gram of MotaZol™ Otic Suspension contains gentamicin sulfate, equivalent to 3 mg gentamicin base; mometasone furoate monohydrate equivalent to 1 mg mometasone furoate; and 10 mg clotrimazole, in a mineral oil-based system containing a plasticized hydrocarbon gel.

PHARMACOLOGY

Gentamicin: Gentamicin sulfate is an aminoglycoside antibiotic active against a wide variety of gram-negative and gram-positive bacteria. *In vitro* tests have determined that gentamicin is bactericidal and acts by inhibiting normal protein synthesis in susceptible microorganisms. In clinical trials, gentamicin was shown to have a range of activity against the following organisms commonly isolated from infected canine ears: *Pseudomonas* spp. (including *P. aeruginosa*), coagulasepositive staphylococci, *Enterococcus faecalis*, *Proteus mirabilis* and beta-hemolytic streptococci.

Mometasone: Mometasone furoate monohydrate is a synthetic adrenocorticoid characterized by a novel (2) furoate 17-ester having chlorine at the 9 and 21 positions, which have shown to possess high topical potency.

Systemic absorption of mometasone furoate ointment was found to be minimal (2%) over 1 week when applied topically to dogs with intact skin. In a 6-month dermal toxicity study using 0.1% mometasone ointment on healthy intact skin in dogs, systemic effects typical of corticosteroid therapy were noted.

The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the integrity of the epidermal barrier. Topical corticosteroids can be absorbed from normal, intact skin. Inflammation can increase percutaneous absorption. Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids.

Clotrimazole: Clotrimazole is a broad-spectrum antifungal agent that is used for the treatment of dermal infections caused by various species of dermatophytes and yeast. The primary action of clotrimazole is against dividing and growing organisms.

In vitro, clotrimazole exhibits fungistatic and fungicidal activity against isolates of *Trichophyton rubrum*, *Trichophyton mentagrophytes*, *Epidermophyton floccosum*, *Microsporum canis*, *Candida* spp., and *Malassezia pachydermatis*. Resistance to clotrimazole is very rare among the fungi that cause superficial mycoses. In an induced otitis externa study using dogs infected with *Malassezia pachydermatis*, 1% clotrimazole in the vehicle formulation was effective both microbiologically and clinically in terms of reduction of exudate, odor, and swelling.

In studies of the mechanism of action, the minimum fungicidal concentration of clotrimazole caused leakage of intracellular phosphorus compounds into the ambient medium with concomitant breakdown of cellular nucleic acids and accelerated potassium efflux. These events began rapidly and extensively after addition of the drug. Clotrimazole is very poorly absorbed following dermal application.

Gentamicin-Mometasone-Clotrimazole: By virtue of its three active ingredients, MotaZol™ Otic Suspension has antibacterial, anti-inflammatory, and antifungal activity. In clinical field trials, MotaZol™ Otic Suspension was effective in the treatment of otitis externa associated with bacteria and *Malassezia pachydermatis*. MotaZol™ Otic Suspension reduced discomfort, redness, swelling, exudate, and odor.

INDICATIONS MotaZol™ Otic Suspension is indicated for the treatment of otitis externa in dogs caused by susceptible strains of yeast (*Malassezia pachydermatis*) and bacteria (*Pseudomonas* spp. [including *P. aeruginosa*], coagulase-positive staphylococci, *Enterococcus faecalis*, *Proteus mirabilis*, and beta-hemolytic streptococci).

CONTRAINDICATIONS If hypersensitivity to any of the components occurs, treatment should be discontinued and appropriate therapy instituted. Concomitant use of drugs known to induce ototoxicity should be avoided. Do not use in dogs with known perforation of eardrums.

WARNINGS The use of these components has been associated with deafness or partial hearing loss in a small number of sensitive dogs (eg, geriatric). The hearing deficit is usually temporary. If hearing or vestibular dysfunction is noted during the course of treatment, discontinue use of MotaZol™ Otic Suspension immediately and flush the ear canal thoroughly with a nonototoxic solution.

Corticosteroids administered to dogs, rabbits, and rodents during pregnancy have resulted in cleft palate in offspring. Other congenital anomalies including deformed forelegs, phocomelia, and anasarca have been reported in offspring of dogs that received corticosteroids during pregnancy.

Field and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.

PRECAUTIONS Before instilling any medication into the ear, examine the external ear canal thoroughly to be certain the tympanic membrane is not ruptured in order to avoid the possibility of transmitting infection to the middle ear as well as damaging the cochlea or vestibular apparatus from prolonged contact.

Administration of recommended doses of MotaZol™ Otic Suspension beyond 7 days may result in delayed wound healing.

If overgrowth of nonsusceptible bacteria or fungi occurs, treatment should be

discontinued and appropriate therapy instituted.

Avoid ingestion. Adverse systemic reactions have been observed following the oral ingestion of some topical corticosteroid preparations. Patients should be closely observed for the usual signs of adrenocorticoid overdosage which include sodium retention, potassium loss, fluid retention, weight gain, polydipsia, and/or polyuria. Prolonged use or overdosage may produce adverse immunosuppressive effects.

Use of corticosteroids, depending on dose, duration, and specific steroid, may result in endogenous steroid production inhibition following drug withdrawal. In patients presently receiving or recently withdrawn from corticosteroid treatments, therapy with a rapidly acting corticosteroid should be considered in especially stressful situations.

TOXICOLOGY Field and safety studies with MotaZol™ Otic Suspension have shown a wide safety margin at the recommended dose level in dogs (see

PRECAUTIONS/ADVERSE REACTIONS).

Gentamicin: While aminoglycosides are absorbed poorly from skin, intoxication may occur when aminoglycosides are applied topically for prolonged periods of time to large wounds, burns, or any denuded skin, particularly if there is renal insufficiency. All aminoglycosides have the potential to produce reversible and irreversible vestibular, cochlear, and renal toxicity.

Mometasone: ALP (SAP) and ALT (SGPT) enzyme elevations, weight loss, anorexia, polydipsia, polyuria, neutrophilia, and lymphopenia have occurred following the use of parenteral, high-dose, and/or prolonged or systemic synthetic corticosteroids in dogs. Cushing's syndrome in dogs has been reported in association with prolonged or repeated steroid therapy.

Clotrimazole: The following have been reported occasionally in humans in connection with the use of clotrimazole: erythema, stinging, blistering, peeling, edema, pruritus, urticaria, and general irritation of the skin not present before therapy.

MotaZol™ Otic Suspension: In field studies following once-daily treatment with MotaZol™ Otic Suspension, ataxia, proprioceptive deficits, and increased water consumption were observed in less than 1% of 164 dogs. In a field study following twice-daily treatment with MotaZol™ Otic Suspension, inflammation of the pinna and diarrhea were observed in less than 1% of 141 dogs.

DOSAGE AND ADMINISTRATION

The external ear canal should be thoroughly cleaned and dried before treatment. Verify that the eardrum is intact. For dogs weighing less than 30 lbs, instill 4 drops from the 7.5 g, 15 g, and 30 g bottles (2 drops from the 215 g bottle) of MotaZol™ Otic Suspension once daily into the ear canal. For dogs weighing 30 lbs or more, instill 8 drops from the 7.5 g, 15 g, and 30 g bottles (4 drops from the 215 g bottle) once daily into the ear canal. Therapy should continue for 7 consecutive days.

HOW SUPPLIED MotaZol™ Otic Suspension is available in

- 7.5 g (NDC 13985-701-07)
- 15 g (NDC 13985-701-15)
- 30 g (NDC 13985-701-30)
- 215 g (NDC 13985-701-21)

plastic bottles.

Store between 2° and 25°C (36° and 77°F). Shake well before use.

USE WITHIN 28 DAYS OF FIRST USE.

U.S. Patent No. 6,127,353.

Made in Germany.

Distributed by: MWI

Boise, ID 83705

www.VetOne.net

Rev. 02/2021

Approved by FDA under

NADA # 141-177

375198 R1

PRINCIPAL DISPLAY PANEL - 215 g Bottle Label

NDC 13985-701-21

215 g

VET one®

MotaZol™

(GENTAMICIN SULFATE,
MOMETASONE FUROATE MONO-
HYDRATE, AND CLOTRIMAZOLE,
OTIC SUSPENSION)

Keep Out of Reach of Children.

Caution: Federal law restricts this drug
to use by or on the order of a licensed
veterinarian.

Approved by FDA under NADA # 141-177

V1 510703

Net Contents: 215g

NDC 13985-701-21

215 g



MotaZol™

(GENTAMICIN SULFATE,
MOMETASONE FUROATE MONO-
HYDRATE, AND CLOTRIMAZOLE,
OTIC SUSPENSION)

Keep Out of Reach of Children.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Approved by FDA under NADA # 141-177

For otic use in dogs only.

Indications: MotaZol™ Otic Suspension is indicated for the treatment of otitis externa in dogs caused by susceptible strains of yeast (*Malassezia pachydermatis*) and bacteria (*Pseudomonas* spp. [including *P. aeruginosa*], coagulase-positive staphylococci, *Enterococcus faecalis*, *Proteus mirabilis*, and beta-hemolytic streptococci).

Each gram contains: gentamicin sulfate, equivalent to 3 mg gentamicin base; mometasone furoate monohydrate equivalent to 1 mg mometasone furoate; and 10 mg clotrimazole, in a mineral oil-based system containing a plasticized hydrocarbon gel.

Dosage and Administration: The external ear canal should be thoroughly cleaned and dried before treatment. Verify that the eardrum is intact. For dogs weighing less than 30 lbs, instill 2 drops from the bottle of MotaZol™ Otic Suspension once daily into the ear canal. For dogs weighing 30 lbs or more, instill 4 drops from the bottle once daily into the ear canal. Therapy should continue for 7 consecutive days.

Store between 2° and 25°C (36° and 77°F).

Shake well before use.

USE WITHIN 28 DAYS OF FIRST USE.

Date Opened: _____

For patent information:


<http://www.merck.com/product/patent/home.html>
27075711

Distributed by: MWI
Boise, ID 83705, www.VetOne.net

Made in Germany.
Rev. 02/2021

V1 510703

Net Contents: 215g



Lot
Exp

varnish and
color free
area

MOTAZOL

gentamicin sulfate, mometasone furoate monohydrate, and clotrimazole suspension

Product Information

Product Type	PRESCRIPTION ANIMAL DRUG	Item Code (Source)	NDC:13985-701
Route of Administration	AURICULAR (OTIC)		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
GENTAMICIN SULFATE (UNII: 8X7386QLRV) (GENTAMICIN - UNII:T6Z9V48IKG)	GENTAMICIN	3 mg in 1 g
MOMETASONE FUROATE MONOHYDRATE (UNII: MTW0WEG809) (MOMETASONE - UNII:8HR4QJ6DW8)	MOMETASONE FUROATE	1 mg in 1 g
		10 mg

361907 R1

CLOTRIMAZOLE (UNII: G07GZ97H65) (CLOTRIMAZOLE - UNII:G07GZ97H65)	CLOTRIMAZOLE	10 mg in 1 g
---	--------------	-----------------

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:13985-701-07	1 in 1 CARTON		
1		7.5 g in 1 BOTTLE, DISPENSING		
2	NDC:13985-701-15	1 in 1 CARTON		
2		15 g in 1 BOTTLE, DISPENSING		
3	NDC:13985-701-30	1 in 1 CARTON		
3		30 g in 1 BOTTLE, DISPENSING		
4	NDC:13985-701-21	1 in 1 CARTON		
4		215 g in 1 BOTTLE, PLASTIC		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NADA	NADA141177	03/15/2015	

Labeler - MWI (019926120)

Revised: 11/2024

MWI